Funding follows successful results in U.S. clinical study and advances FDA regulatory activities for VxWave, an AI-powered robotic ultrasound platform designed to expand

继在美国临床研究中取得成功后，融资随之到位，并推动了VxWave的FDA监管进程。VxWave是一款旨在扩展应用的人工智能驱动机器人超声平台。

access to standardized vascular imaging.

获得标准化血管成像的机会。

SYDNEY

悉尼

,

，

Aug. 6, 2026

2026年8月6日

/PRNewswire/ -- Australian medical robotics company

/美通社/ -- 澳大利亚医疗机器人公司

Vexev

Vexev

today announced it has raised $6 million in new funding to accelerate the path to FDA 510(k) clearance and U.S. commercialization of VxWave, its robotic tomographic ultrasound platform, designed to improve access to standardized vascular imaging. The raise brings Vexev's total funding to date to $19 million..

今日宣布已完成600万美元的新融资，以加速其机器人断层超声平台VxWave获得美国食品药品监督管理局（FDA）510(k)许可并在美国实现商业化。该平台旨在提升标准化血管成像的可及性。此轮融资使Vexev的累计融资总额达到1900万美元。

Cardiovascular disease is the world's leading cause of death, claiming nearly 20 million lives each year.

心血管疾病是全球头号死因，每年夺去近2000万人的生命。

1

1

Yet access to high-quality vascular imaging remains constrained by specialist availability and inconsistent image acquisition. Vexev is developing autonomous robotic imaging technology designed to help address that challenge.

然而，高质量血管成像的获取仍受限于专科医生的可及性以及图像采集的不一致性。Vexev 正在开发自主机器人成像技术，旨在帮助应对这一挑战。

VxWave combines robotics, artificial intelligence and ultrasound imaging to automate vascular ultrasound acquisition. The platform is being developed for upper-limb imaging, with dialysis vascular access as its initial application, where patients require frequent vascular monitoring and healthcare providers face increasing demand for efficient, standardized imaging..

VxWave 将机器人技术、人工智能和超声成像相结合，以实现血管超声采集的自动化。该平台正针对上肢成像进行开发，其初始应用场景为透析用血管通路，此类患者需要频繁的血管监测，而医疗服务提供者则面临着对高效、标准化成像日益增长的需求。

The announcement follows successful results in multi-site clinical study with U.S. Renal Care, one of the nation's largest dialysis providers, showing early clinical validation of VxWave in routine dialysis clinic workflows. During the

该公告紧随与美国最大的透析服务提供商之一 U.S. Renal Care 合作开展的多中心临床研究取得的积极结果，初步验证了 VxWave 在常规透析诊所工作流程中的临床有效性。在此期间

multi-site study

多中心研究

, the VxWave demonstrated a 94% scanning success rate for autonomous vascular imaging by non-specialist clinical staff, with the potential ability to standardize vascular imaging designed to improve consistency and potentially decreasing time to diagnosis and treatment.

VxWave 在由非专科临床医护人员进行的自主血管成像中，展现了 94% 的扫描成功率，具备标准化血管成像的潜力，旨在提高一致性，并可能缩短诊断和治疗的时间。

'We believe high-quality vascular imaging should be available wherever patients receive care, not only when a specialist is available,' said John Carroll, PhD, co-founder and CEO of Vexev. 'We are starting with dialysis patients because the clinical need is clear, but our vision is much broader: to build an autonomous imaging platform that helps clinicians make faster, more consistent and more informed decisions across vascular disease.'.

“我们认为，高质量的血管成像服务应当覆盖患者接受诊疗的所有场所，而不仅仅是在有专科医生可用的情况下才提供，”Vexev 联合创始人兼首席执行官 John Carroll 博士表示。“我们从透析患者入手，因为这一领域的临床需求明确，但我们的愿景更为广阔：打造一个自主成像平台，帮助临床医生在血管疾病诊疗中做出更快速、更一致且更具依据的决策。”

Beyond dialysis vascular access, Vexev intends to expand its autonomous imaging platform into additional vascular disease applications like cardiovascular and peripheral artery disease, while building the clinical evidence needed to support future AI-enabled decisions.

除透析血管通路外，Vexev 计划将其自主成像平台扩展至心血管疾病和外周动脉疾病等更多血管疾病应用领域，同时积累支持未来人工智能辅助决策所需的临床证据。

The fundraise round included participation from existing investors Blackbird Ventures, Neotribe Ventures, Startmate and Horizon, together with new investors TreeArc Investment Group, TEN13, Bioshore Ventures and Alumni Ventures. Funding will support regulatory activities, manufacturing scale-up and commercialization..

本轮融资获得了现有投资者 Blackbird Ventures、Neotribe Ventures、Startmate 和 Horizon，以及新投资者 TreeArc Investment Group、TEN13、Bioshore Ventures 和 Alumni Ventures 的参与。所筹资金将用于支持监管事务、扩大生产规模以及商业化推进。

'Having worked closely with Vexev for several years, I have seen the development of its impressive robot- and AI-based techniques for vascular imaging,' said Anupam Agarwal, MD, Senior Vice President for Medicine and Dean of the Marnix E. Heersink School of Medicine at the University of Alabama at Birmingham, and past president of the American Society of Nephrology.

“与Vexev密切合作数年后，我见证了其在血管成像领域令人印象深刻的机器人及人工智能技术的不断发展。”阿努帕姆·阿加瓦尔医学博士表示。他是阿拉巴马大学伯明翰分校马尼克斯·E·赫林斯克医学院的医学高级副院长兼院长，也曾担任美国肾脏病学会主席。

'The company's initial focus on dialysis vascular access addresses an important challenge for patients and providers, and I believe this technology has the potential to bring meaningful innovation to dialysis patients with vascular access challenges.'.

“公司最初专注于透析血管通路，这解决了患者和医疗服务提供者面临的一项重要挑战。我相信，这项技术有望为存在血管通路问题的透析患者带来具有实质意义的创新。”

About Vexev

关于 Vexev

Vexev is an Australian medical robotics company that develops advanced vascular imaging technology designed to make high-quality scanning more accessible, consistent and scalable. Built by experts in vascular fluid dynamics and computational imaging, Vexev's mission is to improve vascular care by building the next generation of imaging and intelligence tools for clinicians and healthcare providers.

Vexev 是一家澳大利亚医疗机器人公司，致力于开发先进的血管成像技术，旨在使高质量扫描更易于普及、更具一致性且可扩展。Vexev 由血管流体力学和计算成像领域的专家创立，其使命是通过为临床医生和医疗保健提供者打造下一代成像与智能工具，改善血管护理。

Its lead product, VxWave, is being developed as an upper limb vascular imaging platform, with dialysis vascular access serving as its initial application as the company advances toward U.S. commercialization. Learn more at .

其核心产品VxWave正在开发为一款上肢血管成像平台，透析血管通路作为其初始应用场景，公司正朝着在美国实现商业化推进。了解更多请访问。

www.vexev.com

www.vexev.com

.

。

Regulatory Statement

监管声明

VxWave Ultrasound Imaging System is an investigational device and has not been cleared by the U.S. Food and Drug Administration for commercial sale in the United States or by any other regulatory authority for commercial distribution.

VxWave 超声成像系统是一款研究用设备，尚未获得美国食品药品监督管理局批准在美国进行商业销售，也未获得任何其他监管机构批准进行商业分销。

Source:

来源：

https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

SOURCE Vexev

来源 Vexev

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示